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Abstract
 
We have studied the role of secreted immunoglobulin (Ig)M in protection from infection with
influenza virus and delineated the relative contributions of B-1 versus B-2 cell–derived IgM in
this process. Mice deficient in secreted IgM but capable of expressing surface IgM and secreting
other Ig classes show significantly reduced virus clearance and survival rates compared with
wild-type controls. Irradiation chimeras in which only either B-1 or B-2 cells lack the ability to
secrete IgM show mortality rates similar to those of mice in which neither B-1 nor B-2 cells se-
crete IgM. Dependence on both sources of IgM for survival is partially explained by findings in
allotype chimeras that broadly cross-reactive B-1 cell–derived natural IgM is present before in-
fection, whereas virus strain–specific, B-2 cell–derived IgM appears only after infection. Fur-
thermore, lack of IgM secreted from one or both sources significantly impairs the antiviral IgG
response. Reconstitution of chimeras lacking B-1 cell–derived IgM only with IgM-containing
serum from noninfected mice improved both survival rates and serum levels of virus-specific
IgG. Thus, virus-induced IgM must be secreted in the presence of natural IgM for efficient in-
duction of specific IgG and for immune protection, identifying B-1 and B-2 cell–derived IgM
antibodies as nonredundant components of the antiviral response.
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1
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Introduction
 
Two types of IgM can be found in circulation in normal
mice. Natural IgM, secreted mainly by (CD5
 
1
 
) B-1 cells in
the apparent absence of antigen stimulation, constitutes
most of the circulating IgM (1–4) and tends to be polyreac-
tive to both foreign antigens and self-components. In con-
trast, antigen-induced IgM is mostly produced by conven-
tional B (B-2) cells only after antigen stimulation (4). Both
natural and induced IgM are polymeric and as such have
the ability to bind multimeric antigen and to efficiently ac-
tivate the classical complement cascade. In addition, due to
their polymeric structure, IgM can be transported via the
poly-Ig receptor onto mucosal surfaces to provide protec-
tion from pathogenic invasion (5, 6). These unique proper-
ties, and the fact that IgM is the first class of Ig produced
during an infection, allow both natural and antigen-induced
IgM to act as an early defense mechanism against mucosal
and systemic pathogens. Indeed, by creating gene-targeted
mice whose B cells cannot secrete IgM but can express sur-
face IgM and IgD and secrete other classes of Igs (secreted
[s]IgM
 
2
 
/
 
2
 
), we have previously demonstrated a protective
role for natural (B-1 cell–derived) IgM in systemic bacterial
infection (7, 8). These sIgM
 
2
 
/
 
2
 
 mice succumb in greatly
increased numbers to cecal ligation and puncture-induced
acute peritonitis during the first 32 h after infection com-
pared with wild-type controls (8).
The roles of natural and pathogen-induced IgM in im-
mune protection from viral infection are controversial.
Studies with vesicular stomatitis virus (VSV)
 
1
 
 indicated that
virus-induced IgM, secreted early after infection in a T
cell–independent manner, can provide protection from
 
Address correspondence to Nicole Baumgarth, Center for Comparative
Medicine, University of California, Davis, CA 95616. Phone: 530-754-
5813; Fax: 530-752-7914; E-mail: nbaumgarth@ucdavis.edu
 
1
 
Abbreviations used in this paper:
 
 MDCK, Mardin-Darby canine kidney; s,
secreted; VSV, vesicular stomatitis virus.
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acute primary VSV infection (9, 10). In contrast, in studies
in which monoclonal IgM antibodies specific for influenza
virus were passively transferred into SCID mice, Palladino
et al. (11) showed that the transferred IgM antibodies were
protective when given before but not after virus infection.
Thus, the VSV data suggest a role for virus-induced IgM in
immune protection from primary viral infection, whereas
the data from the influenza studies with SCID mice suggest
a protective role only during recall responses. We have
shown previously that only B-2 cells are induced to re-
spond to influenza infection by producing antiviral anti-
bodies but that considerable levels of natural antibodies to
influenza are present in the sera of mice before an infec-
tion, which are produced by B-1 cells (4). As SCID mice
lack both types of IgM, virus-induced and natural, together
the data suggest that both B-1 and B-2 cell–derived IgM
antibodies might have to be present to provide immune
protection against a primary viral infection.
To unequivocally determine the roles of natural and vi-
rus-induced IgM in protection from a primary virus infec-
tion, we have examined the survival rates and antibody re-
sponses after influenza virus infection in sIgM
 
2
 
/
 
2
 
 mice and
in irradiation chimeras that lack sIgM from either B-1 cells
or B-2 cells. Our findings demonstrate that both B-1 and
B-2 cell–derived IgM antibodies are necessary for optimal
immune protection from infection and that one mecha-
nism by which sIgM functions is by positively regulating
the magnitude of the virus-specific IgG response.
 
Materials and Methods
 
Mice and Virus Infection.
 
Mice that lack the ability to secrete
IgM due to a targeted mutagenesis that disrupts expression of the
secreted but not membrane-bound form of IgM (sIgM
 
2
 
/
 
2
 
) have
been described previously (7). Mutant mice on the 129/Sv back-
ground and wild-type 129/Sv mice (sIgM
 
1
 
/
 
1
 
) as well as C57BL/6
and B6.C20 mice were bred and maintained in the Animal Facil-
ity at Stanford University. The reassortant influenza virus strain
Mem71 bearing the hemagglutinin of A/Memphis/1/71 (H3)
and the neuraminidase of A/Bellamy/42 (N1) was harvested and
stored as described (12). Unless otherwise stated, anesthetized
mice were infected intranasally at a virus dose of 1.6 
 
3
 
 10
 
6
 
 PFU
per mouse. The infective dose was determined in preliminary ex-
periments to be the highest virus dose that did not cause mortality
in 3-mo-old 129/Sv wild-type mice.
 
Irradiation Chimera.
 
Irradiation chimeras were constructed us-
ing 2-mo-old lethally irradiated (850 rads) recipients, bone mar-
row as source for B-2 cells, and peritoneal cavity wash-out
(PerC) cells as source of B-1 cells (13). To make chimeras con-
taining IgM-secreting B-1 cells but sIgM
 
2
 
/
 
2
 
 B-2 cells, 5 
 
3
 
 10
 
6
 
PerC cells from sIgM
 
1
 
/
 
1
 
 mice and 3 
 
3
 
 10
 
6
 
 bone marrow cells
from sIgM
 
2
 
/
 
2
 
 mice were transferred into irradiated sIgM
 
2
 
/
 
2
 
 re-
cipients. To construct chimeras containing IgM-secreting B-2
cells but sIgM
 
2
 
/
 
2
 
 B-1 cells, 3 
 
3
 
 10
 
6
 
 bone marrow cells from
sIgM
 
1
 
/
 
1
 
 
 
mice and 5 
 
3
 
 10
 
6
 
 PerC cells from sIgM
 
2
 
/
 
2
 
 mice were
transferred into irradiated sIgM
 
2
 
/
 
2
 
 mice. Control chimeras were
also generated by transferring both bone marrow and PerC cells
from the same donor, i.e., from sIgM
 
2
 
/
 
2
 
 or sIgM
 
1
 
/
 
1
 
 mice. Iden-
tical protocols were used to generate B-1/B-2 allotype-chimeric
mice. For this, lethally irradiated C57BL/6 mice were used as re-
 
cipients of 3 
 
3
 
 10
 
6
 
 C57BL/6 (Igh-b) bone marrow cells and 5 
 
3
 
10
 
6
 
 PerC cells from congenic B6.C20 (Igh-a) mice. Cell suspen-
sions were prepared according to standard methods and injected
intravenously via the tail vein. Chimeras were analyzed or in-
fected 2–3 mo after cell transfers.
 
Virus Plaque Assay.
 
Virus plaque assay was performed accord-
ing to Tannock et al. (14), using Mardin-Darby canine kidney
(MDCK) cells and lung homogenates obtained from mice at dif-
ferent days after influenza virus infection. In brief, fresh lung ho-
mogenates were added at various dilutions in duplicate to semi-
confluent layers of MDCK cells in 6-well tissue culture plates
containing RPMI 1640, 5% FCS, and 5 
 
3
 
 10
 
2
 
4
 
 M 
 
l
 
-glutamine.
Virus infection was allowed to proceed for 45 min at 37
 
8
 
C, and
then cells were overlayed with 0.9% agarose in L-15 medium
(GIBCO BRL) supplemented with 100 U of penicillin, 100 
 
m
 
g/
ml streptomycin, 0.01 M Hepes buffer, pH 6.8, and 0.1% trypsin-
 
l
 
-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK;
Worthington Biochemical Corp.). The culture was incubated for
3 d in a humidified incubator at 37
 
8
 
C containing 5% CO
 
2
 
. Cell
layers were fixed with 5% formaldehyde and stained with a solu-
tion of 0.5% crystal violet in methanol, and plaques were counted
for those dilutions of the lung homogenate at which the number
of plaques was between 10 and 200.
 
ELISA.
 
Serum levels of influenza virus–specific antibodies
were determined by ELISA as described (4). Arbitrary units of vi-
rus-specific Mem71 Ig titers were calculated by comparison to
those of a hyperimmune serum. For comparison of IgM titers
specific for virus strains A/Mem71 (H3N1), A/Guangdong
(H3N2), A/PR8 (H1N1), and B/Panama, ELISAs were carried
out in a similar manner using purified virus antigen from the var-
ious virus strains. Serum titers are expressed in Fig. 6 as reciprocal
dilution of the sera that gave an OD (490 nm) reading of 0.1
(roughly fivefold above background). Total serum IgM was mea-
sured by ELISA using myeloma IgM as standard (4).
 
10-Color FACS
 
®
 
 Analysis and Sort.
 
Single-cell suspensions
from spleens and PerC cells of chimeras 2 mo after adoptive cell
transfer were stained simultaneously with antibody conjugates
specific to CD21–FITC (mAb 7G6) (PharMingen); CD43–PE
(S7); CD5–biotin (53-7.3); CD23–Alexa-594 (B3B4); CD11b–
allophycocyanin (M1/70); IgM Cy7–allophycocyanin (331);
IgM
 
a
 
 Cy7–allophycocyanin (DS-1); IgM
 
b
 
 Cy7–allophycocyanin
(AF6.78); IgD Cy7–PE (1126); IgD
 
a
 
 Cy7–PE (AMS9); IgD
 
b
 
Cy7–PE (AF6.122); CD3–Cascade Blue (CB) or –Cascade Yel-
low (CY); CD4–CY or –CB (GK1.5); CD8–CY or –CB
(53.6.7); macrophage–CY or –CB (F4/80); and CD19–Cy5.5–
allophycocyanin. Streptavidin–Cy5–PE was used as second step
reagent. Noncommercial conjugates and tandem dyes were pre-
pared as outlined previously (15–17). The novel fluorochrome
Cy5.5–allophycocyanin was prepared and conjugated to the anti-
CD19 mAb with a method similar to that described for Cy7–allo-
phycocyanin (17). Propidium iodide was added at 0.25 
 
m
 
g/ml.
Cells were assayed using a modified triple laser Cytomation/Bec-
ton Dickinson hybrid FACS
 
®
 
 (described in references 18 and 19),
and data were analyzed with the FlowJo software (TreeStar Inc.).
CD3
 
1
 
CD4
 
1
 
CD19
 
2
 
 T cells from single-cell suspensions of
mediastinal lymph nodes from day 7 influenza virus–infected
sIgM
 
2
 
/
 
2
 
 and sIgM
 
1
 
/
 
1
 
 mice were sorted after staining with CD3–
FITC, CD4–PE, and CD19–allophycocyanin on the Cytoma-
tion/Becton Dickinson hybrid FACS
 
®
 
. Purity of sorted cells was
 
.
 
96% as assessed by FACS
 
®
 
 immediately after sorting.
 
Proliferation Assay.
 
FACS
 
®
 
-purified mediastinal lymph node
CD4
 
1
 
 T cells from sIgM
 
2
 
/
 
2
 
 and wild-type mice were cultured at
indicated numbers in DMEM/10% FCS/5 
 
3 
 
10
 
2
 
5
 
 M 
 
b
 
-ME, 216
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mg/liter 
 
l
 
-glutamine, and antibiotics in the presence of 2.5 
 
3
 
 10
 
5
 
irradiated splenic feeder cells per well. Splenic feeder cells were
pulsed with 200 hemagglutinin units of Mem71 or with PBS for
90 min before irradiation. Cells were incubated for 24 h at 37
 
8
 
C
in 7.5% CO
 
2
 
/92.5% air and then pulsed with 0.5 
 
m
 
Ci [methyl-
 
3
 
H]thymidine. Cells were harvested after a further 8-h culture pe-
riod onto filter mats, and incorporated radioactivity was measured
using a liquid scintillation counter.
 
Reconstitution of Chimeric Mice with Polyclonal IgM.
 
Wild-type
mice and sIgM
 
2
 
/
 
2
 
 mice were bled via the tail vein, and serum
was stored in aliquots at 
 
2
 
20
 
8
 
C until used. Groups of chimeric
animals reconstituted with wild-type bone marrow and PerC
cells from sIgM
 
2
 
/
 
2
 
 mice
 
 
 
were injected intraperitoneally with 0.5
ml of wild-type serum 1 h before influenza virus infection to re-
store polyclonal IgM (
 
n
 
 5 
 
11). Serum injections were repeated
daily for 5 d after infection. Control mice were given the same
amount of serum from sIgM
 
2
 
/
 
2
 
 mice.
 
Statistical Analysis.
 
Statistical analyses were carried out using
the nonparametric Wilcoxon/Kruskal/Wallis rank test or two-
tailed Student’s 
 
t
 
 test when appropriate. Survival data were ana-
lyzed by Log Rank Test with the Kaplan-Meier method. Data
are considered statistically significant when
 
 P 
 
, 
 
0.05.
 
Results
 
Reduced Survival of sIgM
 
2
 
/
 
2
 
 Mice after Influenza Virus Infec-
tion.
 
To determine whether sIgM provides immune pro-
tection during acute influenza virus infection, sIgM
 
2
 
/
 
2
 
mice and wild-type controls at 2 and 3 mo of age were in-
fected intranasally with 1.6 
 
3
 
 10
 
6
 
 PFU of influenza virus
Mem71. This virus dose was chosen because preliminary
studies had shown that it was the maximal virus dose that
did not cause deaths in 3-mo-old wild-type mice (data not
shown). As shown in Fig. 1, the same virus dose caused
50% mortality of sIgM
 
2
 
/
 
2
 
 mice (P , 0.0001). At a younger
age (2 mo), when mice were more susceptible to influenza
virus infection, still significantly higher percentages of
sIgM2/2 mice died from infection than wild-type mice (80
vs. 40%, respectively; P , 0.04). Most deaths occurred be-
tween days 6 and 10 after infection. Secretion of IgM is
only one immune mechanism that contributes to the clear-
ance of influenza virus infection, however, as infections
with lower doses of virus (0.2, 0.4, and 0.8 3 106 PFU per
mouse) did not cause deaths in 3-mo-old sIgM2/2 mice
nor in age-matched wild-type controls (data not shown).
Increased Viral Load in Lungs of sIgM 2/2 Mice. Lung vi-
rus titers from groups of sIgM2/2 and wild-type mice at
days 3, 5, 7, and 10 after influenza virus infection were de-
termined to assess whether the increased mortality of
sIgM2/2 mice was associated with a higher viral load at the
site of virus replication. Whereas the viral titers in lungs of
sIgM2/2 and control mice were comparable early after in-
fection (day 3), at days 5 and 7 after infection there was a
significant (P , 0.05) increase in lung virus load of sIgM2/2
mice that survived until that time compared with wild-type
controls (Fig. 2). Those sIgM2/2 mice that survived the in-
fection cleared the virus around day 10, similar to wild-
type mice. Thus, the absence of sIgM is associated with a
significant increase in viral load in the respiratory tract
shortly before virus-induced deaths are observed. As we
could perform MDCK assays only on the lungs of surviving
mice, it is possible that at time points later than day 5, mice
with even higher viral loads died preferentially and thus
that these measurements underestimate the differences in
the viral loads of these mice.
Impaired Antiviral IgG Responses in the Absence of sIgM.
To determine the antibody responses to influenza virus in-
fection, serum levels of anti–influenza virus-specific Igs in
wild-type and sIgM2/2 mice were assayed by ELISA. As
expected, considerable levels of virus-binding natural IgM
antibodies were present in wild-type mice before infection,
and virus-specific IgM levels were further induced by in-
fection (Fig. 3). No virus-specific IgM was detected in the
sIgM2/2 mice. The sIgM2/2 mice responded to influenza
virus infection, but the levels of virus-specific IgG2a were
significantly reduced compared with wild-type controls
(Fig. 3). By day 22 after infection, the levels of virus-spe-
Figure 1. Increased influenza virus–induced mortality in mice lacking
sIgM. Groups of 2- (n 5 14; left panel) and 3-mo-old (n 5 10; right
panel) sIgM2/2 and sIgM1/1 mice were infected with influenza virus
Mem71, and survival was monitored daily. Percentages of survival are
shown as a function of time.
Figure 2. Reduced virus clearance in the lungs of sIgM2/2 mice.
Groups of 3-mo-old sIgM2/2 and sIgM1/1 mice (10–12 per time point)
were infected with influenza virus Mem71, and lung homogenates were
prepared at indicated times after infection. Lung virus titers were deter-
mined by MDCK cell plaque assay. Statistical analysis was determined us-
ing the Wilcoxon Rank Test.
274 Natural and Acquired IgM in Influenza Virus Infection
cific IgG2a were comparable between sIgM2/2 mice and
wild-type controls. In addition, the levels of virus-specific
IgG1 in sIgM2/2 mice were significantly reduced on day 7
after infection compared with control mice. As IgG2a is
the predominant IgG isotype produced in response to virus
infection (20, 21), these results suggest that one mechanism
by which sIgM protects the host from influenza virus infec-
tion is by promoting an efficient neutralizing IgG antibody
response.
Lack of sIgM Does Not Affect the Height of the Virus-specific
CD41 Th Cell Response. As cell-mediated immune mech-
anisms are known to mediate protection from influenza vi-
rus infection (22), we investigated whether the lack of IgM
affects virus-induced T cell responses. The overall cellular-
ity of mediastinal lymph nodes and spleen and lung paren-
chyma before and at day 7 after infection, the peak of the
cellular response (23), was comparable in these mice (data
not shown). Extensive FACS® analysis did not reveal signif-
icant differences in the number of T cells, the ratio of
CD41/CD81 T cells, or the frequency of activated T cells
accumulating in lung parenchyma of sIgM2/2 and wild-
type mice before and at day 7 of infection (data not shown).
In the draining mediastinal lymph nodes that become
visible only after influenza virus infection (12), the fre-
quency of CD191 B cells was reduced and CD31 T cell
numbers were increased in sIgM2/2 mice compared with
wild-type controls (Fig. 4 A). The ratio of CD4/CD8 was
similar, z3:1 in both groups of mice. Thus, CD41 T cell
recruitment/accumulation in the draining lymph nodes is
not negatively affected by the lack of sIgM.
FACS®-purified CD41 T cells from mediastinal lymph
nodes 7 d after influenza virus infection were stimulated in
vitro with virus-pulsed APCs, and proliferation was deter-
mined by measuring [3H]thymidine incorporation. The re-
sults, shown in Fig. 4 B, demonstrate that CD41 T cells
from both types of mice responded to virus-pulsed APCs
Figure 3. Impaired virus-specific IgG response in the absence of sIgM.
Groups of 3-mo-old sIgM2/2 and sIgM1/1 mice (n 5 10) were infected
with influenza virus Mem71. Mice were bled at indicated times, and the
titers of influenza virus–specific IgM, IgG1, and IgG2a were measured by
ELISA. Arbitrary units of antivirus Ig per milliliter were determined by
comparison to a standard hyperimmune serum.
Figure 4. Lack of sIgM does
not affect the T helper response
in sIgM2/2 mice. Respiratory
tract draining mediastinal lymph
nodes were isolated from sIgM2/2
and sIgM1/1 mice 7 d after in-
fection with influenza A/Mem71.
(A) Frequencies of B cell
(CD191) and CD41 and
CD81CD31 T cell populations
in the mediastinal lymph nodes
were assessed by FACS®. (B) In-
dicated numbers of FACS®-puri-
fied CD31CD41 T cells from
sIgM2/2 and sIgM1/1 mice were
cultured in the presence of
Mem71 virus–pulsed (closed
symbols) or nonpulsed (open
symbols) irradiated splenic APCs.
Incorporation of [3H]thymidine
was determined as a measure of
T cell proliferation.
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with a roughly eightfold increase in proliferation compared
with nonpulsed APCs, suggesting that similar frequencies
of influenza-virus specific CD41 T cells are induced in the
draining lymph nodes of wild-type and sIgM2/2 mice and
therefore that the presence of sIgM does not affect the
magnitude of the antigen-reactive CD41 T cell response.
Thus, disturbance of the humoral immune response alone
in the presence of an apparently normal T cell response
leads to an increase in mortality rates after acute influenza
virus infection.
B-1 and B-2 Cell–derived IgM Antibodies Differ in Virus
Recognition. We previously showed that influenza virus–
binding sIgM is provided by two sources, B-1 cells and B-2
cells (4). To delineate the contributions of B-1 and B-2
cell–derived IgM on protection from influenza virus infec-
tion, we generated irradiation chimeras using allotype-con-
genic wild-type C57BL/6 (Igh-b) and B6.C20 (Igh-a)
mice. In these mice, B-1 and B-2 cells and their sIgs can be
distinguished with allotype- and isotype-specific mAbs. In
recipients of Igh-b–expressing bone marrow cells and Igh-
a–expressing PerC cells 2–3 mo after transfer, at least 85–
90% of B-1 cells in the peritoneal cavity are PerC cell do-
nor derived, whereas more than 99% of B-2 cells are bone
marrow derived (Fig. 5). Similar results were found for the
spleen (data not shown). In these recipients, about two-
thirds of serum IgM is PerC cell derived and one-third is
bone marrow donor derived (Igh-a, 570 mg/ml; Igh-b, 240
mg/ml; mean titers, n 5 10).
To determine the contributions of B-1 and B-2 cells on
virus-specific serum IgM levels, we determined by ELISA
the titers of a- and b-allotype IgM that can react with a
panel of four influenza virus strains before and 7 d after in-
fection with influenza virus A/Mem71. The results, sum-
marized in Fig. 6, reveal large differences in both titers and
binding properties of IgM antibodies derived from these
two different cell populations. Before infection with influ-
enza virus, considerable titers of virus-binding IgM anti-
bodies are found in the sera that can bind to at least four
different influenza virus strains (A/Mem71, A/Guangdong,
A/PR8, and B/Panama). Consistent with our previous
findings (4), these presumably cross-reactive IgM antibod-
ies are derived mainly from B-1 (Igh-a) cells. B-2 cell–
derived virus-binding IgM antibodies, present at very low
levels before infection, are induced significantly after infec-
Figure 5. Adoptive cell transfer of
bone marrow and PerC cells results in
B-1/B-2 chimerism. Lethally irradiated
C57BL/6 mice were reconstituted with
bone marrow cells from C57BL/6
(Ighb) and PerC cells from congenic
B6.C20 (Igha) mice. 2 mo after cell
transfer, PerC cells were taken from the
recipients, stained with indicated anti-
bodies, and analyzed using 10-color
flow cytometry. Shown are 5% contour
plots of cells gated for exclusion of pro-
pidium iodide and expression of the
pan-B cell marker CD19. B-1 and B-2
cells were distinguished by differences
in their expression of total and allotype-
specific IgM and IgD. B-1 cells were
further distinguished from B-2 cells by
their expression of CD11b (MAC-1)
and their low expression of CD21 (data
not shown). Percentages indicate fre-
quencies of cells in gate of all PerC
(CD191) B cells.
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Figure 6. Reactivity of B-1
and B-2 cell–derived IgM anti-
bodies before and after infection
with influenza virus A/Mem71.
Sera from B-1/B-2 allotype-chi-
meric mice, generated as outlined
in the Fig. 5 legend, were taken
before and 7 d after infection
with influenza virus A/Mem71 to
determine the titers of B-1 (Igh-
a) and B-2 (Igh-b) cell–derived
antibodies able to bind four dif-
ferent influenza virus strains as
indicated. Indicated are antiviral
titers, determined by ELISA as
reciprocal of the serum dilution
that resulted in an OD 490 nm
reading significantly higher than
that of the background. n.s., not
significant.
Figure 7. IgM antibodies secreted by both B-1 and B-2 cells are neces-
sary for survival from influenza virus infection and for maximal antiviral
IgG2a response. (A) Irradiation chimeras containing B-1 and B-2 cells
from indicated sources were constructed as described in Materials and
Methods. 2 mo after reconstitution, groups of chimeras (n 5 9) were in-
fected with influenza Mem71 at the indicated virus doses, and survival
was monitored daily after infection. Similar results were obtained in two
independent experiments after infection with 1.6 3 106 PFU per mouse.
(B) Chimeras infected with influenza virus Mem71 at 0.8 3 106 PFU per
mouse were bled at indicated times after influenza virus infection, and se-
rum levels of virus-specific IgM and IgG2a antibodies were determined
by ELISA. Arbitrary units of antivirus Ig per milliliter are shown.
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tion with influenza A/Mem71. In contrast to the B-1 cell–
derived IgM, however, these infection-induced B-2 cell–
derived antibodies show greatly reduced reactivity with the
other influenza A virus strains and, importantly, they show
virtually no cross-reactivity with the influenza B virus
strain B/Panama (Fig. 6). Thus, B-1 and B-2 cell–derived
IgM antibodies recognize different antigens on the virus.
The broad specificity of the B-1 cell–derived antibodies
might suggest their binding to carbohydrate moieties on
the virus, whereas the more restricted recognition pattern
of the B-2 cell–derived IgM antibodies could suggest rec-
ognition of virus-specific peptide determinants.
Survival of Influenza Virus Infection Is Dependent on the
Presence of Both Natural and Virus-induced IgM. To assess
the effects of the presence of natural and virus-induced
IgM on the survival from influenza virus infection, we
constructed irradiation chimeras that contained natural
IgM–secreting B-1 cells but sIgM2/2 B-2 cells or vice versa
using a protocol identical to that used to generate the allo-
type chimeras. After infection with 0.8 3 106 PFU per
mouse, chimeras that lacked either natural IgM or virus-
induced IgM died at a rate (z50%) similar to that of chi-
meras lacking both natural and virus-induced IgM (Fig. 7
A). In contrast, none of the chimeras that had received
both natural IgM–secreting B-1 cells and virus-induced
IgM–secreting B-2 cells died from the infection (P ,
0.0001). When challenged with 1.6 3 106 PFU per mouse,
chimeras that lacked natural IgM died considerably earlier
(at day 3) than chimeras that lacked virus-induced IgM, al-
though their final survival rates were similar (Fig. 7 A).
Taken together, the data demonstrate that natural and in-
duced IgM antibodies derived from B-1 and B-2 cells, re-
spectively, represent nonredundant immune mechanisms
that provide protection against influenza virus infection.
Natural IgM appears to function early, before virus-induced
IgM becomes available.
Both B-1 and B-2 Cell–derived IgM Antibodies Are Re-
quired for Optimal Antiviral IgG2a Response. 2 mo after
cell transfer, chimeras containing IgM-secreting B-1 cells,
B-2 cells, or both B-1 and B-2 cells had similar levels of
total serum IgM (991 6 134 mg/ml, 1,167 6 74 mg/ml,
and 1,274 6 113 mg/ml, respectively). Consistent with
the data from the allotype-chimeric mice (Fig. 6), chime-
ras containing IgM-secreting B-1 but lacking IgM-secret-
ing B-2 cells had normal levels of virus-binding IgM. The
levels of natural virus-binding IgM did not increase signif-
icantly in these mice after infection (Fig. 7 B). In contrast,
the levels of virus-specific IgM were significantly induced
after influenza virus infection in chimeras containing ei-
ther IgM-secreting B-2 cells and sIgM2/2 B-1 cells, or
both B-1 and B-2 IgM-secreting cells.
Within the first 10 d of virus infection, serum levels of
virus-specific IgG2a were significantly lower in chimeras in
which either only one type of B cell or none of the B cells
was capable of secreting IgM as compared with chimeras
with IgM-secreting B-1 and B-2 cells (Fig. 7 B). By day 14
after infection, antiviral IgG2a titers in chimeras that con-
tained IgM-secreting B-2 cells but sIgM2/2 B-1 cells
reached the same levels as in chimeras with IgM-secreting
B-1 and B-2 cells. In contrast, in the absence of B-2 cell–
derived IgM but with B-1 cell–derived IgM, the IgG2a
titers remained significantly lower even at day 21 after in-
fection. Thus, in the absence of either B-1 cell–derived nat-
ural IgM or B-2 cell–derived virus-induced IgM, antiviral
IgG2a responses are impaired, but B-2 cell–derived virus-
induced IgM appears to have a stronger overall effect.
Application of Normal Serum IgM Alters the Outcome of In-
fection in sIgM2/2 Mice. The requirement for both natural
and virus-induced IgM in optimal protection from influ-
enza virus infection was further tested with chimeric mice
that contained wild-type B-2 cells and sIgM2/2 B-1 cells.
To reconstitute natural IgM in these mice, normal serum
was injected 1 h before infection and daily thereafter for
5 d. A control group received serum from sIgM2/2 mice.
Injection of wild-type serum significantly increased virus-
binding natural IgM levels; however, the levels did not
reach those in control mice reconstituted with wild-type
Figure 8. Reconstitution of natural IgM–deficient chimeras results in
increased survival and increased antiviral IgG2a serum titers after influenza
virus infection. Lethally irradiated recipients were reconstituted with
bone marrow from wild-type mice and PerC cells from sIgM2/2 mice
(B-1 sIgM2/2). Chimeras received daily injections of 0.5 ml of normal se-
rum (sIgM1/1 serum; n 5 10) or IgM-deficient serum (sIgM2/2 serum;
n 5 10) immediately before infection and daily for 5 d after infection.
Control mice received both bone marrow and PerC cells from sIgM1/1
mice (B-1 sIgM1/1). (A) Survival from infection with influenza A/Mem71
was monitored daily for 28 d. (B) Mem71-binding serum IgM titers were
determined by ELISA in groups (n 5 9) of noninfected chimeras after 3 d
of daily injections with the indicated type of serum or in controls. Arbi-
trary units of antivirus Ig per milliliter are shown. (C) Mem71-specific
IgG2a titers in the sera of indicated groups of irradiation chimeras were
determined at day 8 after infection with influenza A/Mem71 by ELISA.
Arbitrary units of antivirus Ig per milliliter are shown.
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B-1 and B-2 cells (Fig. 8 B). This partial reconstitution of
virus-binding natural IgM increased the levels of survival
(Fig. 8 A) compared to controls injected with sIgM2/2 se-
rum and to irradiation chimeras lacking both B-1 and B-2
cell–derived IgM. Consistent with the overall protective
effect of administered natural IgM, the virus-specific IgG2a
response on day 8 after infection in reconstituted animals
was significantly increased compared with that seen in the
control mice and reached levels similar to those in chimeras
reconstituted with IgM-secreting B-1 and B-2 cells. Thus,
the presence of natural IgM alone at the time of infection is
insufficient to rescue sIgM2/2 mice from death or to affect
the height of the virus-specific IgG2a response. However,
in conjunction with the early virus-induced IgM, full im-
mune protection is achieved.
Discussion
Humoral responses to influenza virus infection in mice
are provided by two discrete B cell populations: B-1 cells,
which provide virtually all of the preexisting natural IgM
antibodies, and B-2 cells, which secrete almost all of the in-
fection-induced antiviral IgM and IgG2a antibodies (Fig. 6)
(4). In this study, we demonstrate that IgM antibodies de-
rived from both B-1 and B-2 cells can provide immune
protection against influenza virus infection provided that
they are both present. The lack of sIgM from either of the
two B cell populations results in enhanced mortality similar
to that seen in mice that lack both B-1 and B-2 cell–derived
IgM. Furthermore, replenishment of mice lacking only B-1
cell–derived antibodies with normal serum IgM increases
their rates of survival after infection. Thus, the effects of
B-1 and B-2 cell–derived IgM are nonredundant and act in
concert to provide full immune protection.
The requirement for IgM from both B-1 and B-2 cells
suggests that IgM from the two cell types may function via
discrete cooperating mechanisms to confer protection or
that the antibodies might act at different times and/or loca-
tions after infection. Chimeras containing virus-induced
IgM from B-2 cells but lacking natural IgM from B-1 cells
appear to die sooner after infection than chimeras with nat-
ural IgM but no virus-induced IgM (Fig. 7 A). The preex-
isting, broadly reactive, B-1 cell–derived IgM may be re-
quired to provide initial protection against a novel viral
pathogen before a stronger and more specific B-2 cell–
derived IgM response is induced (Fig. 6). In the absence of
natural IgM, very few antiviral antibodies are present when
infection first occurs. Although the B-2 antibody response
is induced, it may not be induced rapidly enough to confer
optimal protection. Conversely, in the absence of virus-
induced B-2 cell–derived IgM, the levels of natural IgM do
not significantly increase (Fig. 6 and Fig. 7 B) and may not
be sufficient to control the increasing viral load.
Our data demonstrate a clear role for B-1 cells in early
protection from an acute viral infection. Together with our
earlier demonstration that death from acute cecal puncture
and ligation-induced sepsis is prevented by administration
of B-1 cell–derived phosphatidyl choline–specific IgM an-
tibodies (8), we have come closer to understanding the role
of this cell population in immune protection. Protection
from influenza virus infection by B-1 cell–derived IgM an-
tibodies does not entail significant increases in their normal
serum levels after infection (Fig. 6; reference 4), suggesting
that clonal expansion and increased IgM secretion is not
initiated in vivo after infection. This is consistent with ob-
servations in vitro that B-1 cells do not respond to cross-
linking of the B cell receptor with proliferation, possibly
due to the expression of inhibitory coreceptors such as
CD5 (24). However, B-1 cells can respond to certain T
cell–dependent antigens with increased antibody produc-
tion (25), leaving open the possibility that increased focal
production of antiviral IgM might occur only locally in the
respiratory tract that binds to antigen and thus can not be
detected in the serum.
A number of studies have demonstrated that passive
transfer of immune serum or monoclonal antiviral antibod-
ies can provide protection from influenza virus infection (6,
11, 26–29). In addition, B cell–deficient mice were shown
to have reduced survival rates after influenza virus infection
(6, 30). Our findings are consistent with these observations,
confirming that B cells and B cell products are part of the
protective immune responses to influenza virus infection.
Furthermore, by demonstrating that both natural and virus-
induced IgM are required for protection, our findings ex-
plain the apparently normal clearance of influenza virus in
the absence of CD41 T cells (31, 32). Although nude mice
and mice deficient in CD41 T cells lack the ability to
mount T cell–dependent antibody responses, they should
have normal levels of natural IgM and can mount T cell–
independent IgM responses (10). Together with other im-
mune defense mechanisms, such as the virus-specific CD81
T cell response, these IgM responses are apparently suffi-
cient to provide the observed immune protection.
Our findings also help to explain the apparent discrep-
ancy concerning the role of sIgM during acute primary in-
fection with VSV and influenza virus. Studies on VSV
showed that the early induction of IgM antibodies confers
immune protection during primary infection (9, 10). In
contrast, transfer of monoclonal anti–influenza virus-spe-
cific IgM antibodies into SCID mice was shown to be pro-
tective only when antibodies were given before infection
(11), indicating that IgM antibodies are protective only
during recall responses. Similar to the transfer of antibodies
into SCID mice after initiation of infection, chimeras that
lack natural IgM from B-1 cells can mount a normal B-2
cell antibody response but are still susceptible to infection
(Fig. 7 A). The failure to protect SCID mice by transfer of
monoclonal virus-specific IgM antibodies after initiation of
infection is probably because SCID mice lack preexisting
B-1 cell–derived natural IgM antibodies. Consistent with
this notion, we show here (Fig. 8 A) that transfer of natural
IgM–containing serum into mice deficient only in natural
IgM can increase survival after influenza virus infection.
Thus, the outcome of a primary infection with influenza
virus, similar to that of a primary infection with VSV, is
critically influenced by the presence of sIgM.
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A question that arises from our studies is how sIgM pro-
vides immune protection against a viral infection. Binding
of virus by IgM may neutralize viral infectivity (33) or may
lead to complement activation and promote clearance by
phagocytic cells via complement receptor–mediated uptake
(34). Our studies also reveal a previously unsuspected mech-
anism by which sIgM can confer protection against virus in-
fection: by promoting an efficient antiviral IgG response
(Fig. 3). Consistent with the requirement for both natural
and virus-induced IgM for maximal survival from an acute
viral infection, both IgM antibodies are required for effi-
cient induction of the IgG response, in particular the induc-
tion of virus-specific IgG2a (Fig. 7 B). Thus, sIgM protects
from viral infection at least in part by promoting an efficient
IgG response to the virus. The isotype most strongly af-
fected by the lack of IgM depends on the type of antigen
encountered. The induction of IgG2a, the predominant iso-
type produced in response to influenza virus infection (20,
21), is most severely decreased in sIgM2/2 mice (Fig. 3).
Other studies had shown that IgG1, the predominant iso-
type response to KLH (35), is most severely reduced in
sIgM2/2 mice after KLH immunization (7, 36). The pres-
ence of sIgM therefore maximizes the induction and/or se-
cretion of antigen-specific IgG (Fig. 3).
The requirement for sIgM in the antiviral IgG response
is consistent with our previous observations showing that
sIgM is required for efficient IgG antibody response to sub-
optimal doses of T cell–dependent antigens (7, 36). How-
ever, the respective roles of pre-existing natural IgM and
antigen-induced IgM in the ensuing IgG response were not
delineated in those previous studies. The impaired IgG re-
sponses in chimeras lacking either natural or virus-induced
IgM clearly show that both IgM are required, although an-
tigen-induced IgM from B-2 cells appears to have a stron-
ger effect (Fig. 7 B). The lack of sIgM seems to directly af-
fect the B cell and not the helper T cell response. B cell
accumulation and/or recruitment into the respiratory tract
draining lymph nodes is reduced after influenza virus infec-
tion in sIgM2/2 mice compared with controls, whereas the
CD41 T cell response appears normal (Fig. 4).
Although the precise mechanisms by which IgM en-
hances the B cell response are not known, because comple-
ment and complement receptors are crucial for the induc-
tion of normal antibody responses (37–39), previous studies
proposed that natural IgM antibodies augment IgG re-
sponses by activating complement to form immune com-
plexes (7, 36). These complexes may then activate B cells
by cross-linking B cell receptors and/or be trapped on folli-
cular dendritic cells for efficient germinal center reaction.
The fact that the newly induced IgM is more effective at
promoting IgG response than natural IgM suggests that fo-
cal secretion of virus-specific IgM immediately after B cell
activation may directly activate the IgM-secreting B cells
for IgG production. As discussed more extensively else-
where (40), sIgM might act directly on the B cells in an au-
tocrine fashion through engagement of their complement
receptors, which are known to provide important costimu-
latory signals (39). Such engagement of complement recep-
tors could lead to increased B cell activation and prolifera-
tion and therefore an increase in the size of the initial B cell
response. Alternatively, polymeric IgM might enhance an-
tigen-mediated Ig receptor triggering by cross-linking sur-
face Ig receptors on B cells that have bound the antigen,
thus also affecting clonal burst size. The reduced number of
B cells found in the draining lymph nodes of the respiratory
tract 7 d after influenza virus infection in sIgM2/2 mice
compared with control mice (Fig. 4 A) further supports the
notion that sIgM enhances early clonal expansion of anti-
gen-specific B cells.
In summary, we provide clear evidence for a critical role
for sIgM, and therefore for the humoral immune response,
in immune protection from acute influenza virus infection.
We also show that, perhaps because of temporal and/or
spatial constraints, IgM secreted by both B-1 and B-2 cells
is required for optimal protection against infection. B-1
cell–derived natural IgM appears to provide initial defense,
whereas B-2 cell–derived, virus-stimulated IgM provides
additional protection and functions as an autocrine regula-
tor that, in concert with B-1 cell–derived IgM, boosts effi-
cient IgG responses to the virus.
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